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Evidence that host immunity plays a critical 
role in limiting tumor outgrowth in the early 
stages of tumorigenesis supports the notion of 
immune surveillance (1, 2). However, to ef-
fectively function, endogenous or adoptively 
transferred tumor-specifi   c T cells must be 
present in reasonable numbers, maintain their 
tumor specifi  city and an activated phenotype, 
traffi   c to the tumor site, and kill their targets 
in situ. Unfortunately, priming tumor-specifi  c 
T cells and sustaining an immune response that 
imparts a measurable clinical benefi  t is lim-
ited by the ability of tumors to modify their 
microenvironment (3). These immunosuppres-
sive mechanisms are also present in transplant-
able mouse tumors in which stable cell lines 
are generated after multiple in vivo passages 
that ultimately select for clones able to avoid 
immune recognition. As such, these models 
represent useful tools to identify the cellular and 
molecular tumor-induced immunosuppressive 
pathways, as well as discover pharmacological 
targets and screen immunomodulatory drugs 
with measurable antitumor activity.
Extensive data exist in mouse models 
correlating tumor progression with the accu-
mulation of myeloid inhibitory cells such as 
CD11b+/Gr-1+ myeloid-derived suppressor 
cells (MDSCs) (4), immature dendritic cells (5), 
and F4/80+ macrophages (6) that induce local 
and possibly systemic immunosuppression (7). 
l-Arginine metabolism is an important path-
way used by MDSCs to blunt antitumor 
  immunity (8). In these cells, arginase-1 (ARG1) 
and nitric oxide synthase–2 (NOS2), the key 
enzymes in l-arginine catabolism, work ei-
ther alone or synergistically to suppress T cell 
function (9). The elimination, functional 
inhibition, or diff   erentiation of MDSCs in 
tumor-bearing hosts can restore CD8+ T cell 
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responsiveness (10, 11), thereby implicating their role in 
  tumor-induced immunosuppression.
By increasing the intracellular concentrations of cyclic 
guanosine monophosphate (cGMP), phosphodiesterase-5 
(PDE5) inhibitors such as sildenafi  l  (Viagra),  vardenafi  l 
(Levitra), and tadalafi  l (Cialis) have been used therapeutically 
to treat erectile dysfunction (12), pulmonary hypertension 
(13), and cardiac hypertrophy (14). More recently, they were 
shown to induce apoptosis in diff  erent human tumors such as 
colon carcinoma and chronic lymphocyte leukemia (15, 16). 
In our mouse models, we show that pharmacologic PDE5 
blockade down-regulates MDSC suppressive pathways and 
restores antitumor immunity. Moreover, our in vitro experi-
ments using PBMCs from multiple myeloma (MM) and head 
and neck cancer patients suggest that the same mechanisms 
found in mice are also present in humans and demonstrate a 
possible role for PDE5 inhibitors as an immune adjuvant in 
the clinical setting.
RESULTS
PDE5 inhibition augments immune-mediated antitumor 
activity in vivo
When administered in vitro, PDE5 inhibition induces apopto-
sis in colon carcinoma (15) and chronic lymphocytic leuke-
mia cells (16). To determine whether similar eff  ects could be 
observed in vivo, we used various transplantable mouse tu-
mors, including CT26WT (a colon carcinoma; Fig. 1 A), the 
more aggressive variant C26GM (Fig. 1 B), TS/A (a mam-
mary adenocarcinoma; Fig. 1 C), and the MCA203 fi  bro-
sarcoma (Fig. 1 D). PDE5 inhibitors were administered 
starting on the day of tumor challenge. Sildenafi  l and tadala-
fi  l signifi  cantly delayed tumor outgrowth by 50 to 70% in 
immune-competent mice, although all mice ultimately died 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20061104/DC1). Similar results were obtained even if 
sildenafi  l treatment was started on day 7 after tumor challenge 
in the CT26WT model (Fig. S2). The fact that no diff  erence 
in tumor outgrowth was seen between early versus late 
administration of sildenafi   l suggests that PDE5 inhibition 
does not appreciably aff  ect the early phases of tumor uptake 
but rather infl  uences the later stages of tumor outgrowth. 
Because the addition of sildenafi  l to cultured CT26WT cells 
did not increase their apoptosis or aff   ect their doubling 
time (unpublished data), we conclude that sildenafi  l does 
not have a direct antitumor eff  ect but rather interferes in 
host–  tumor interactions.
To confi  rm that the antitumor eff  ect of PDE5 inhibitors 
was immune mediated, the experiments were repeated in 
  immune-compromised BALB/c-Rag-2−/− mice (Fig. 1, A–C). 
In these hosts, sildenafi  l demonstrated no antitumor effi   cacy. 
Because these mice lack T and B lymphocytes but have normal 
or enhanced NK and NKT activity (17, 18), these results 
strongly suggest that the antitumor activity of PDE5 inhibition 
in our models is primarily caused by an adaptive immune re-
sponse with either minimal NK/NKT-mediated activity, direct 
tumor-induced apoptosis, or tumor angiogenesis inhibition.
Evidence of an immune-mediated, antitumor eff  ect of 
PDE5 inhibition is further shown by tetramer analysis on 
splenocytes obtained from sildenafi  l-treated, CT26WT tumor-
bearing mice, which revealed a higher number of CTLs spe-
cifi  c for AH-1 (unpublished data), a CT26 tumor-associated 
antigen, as compared with their untreated counterparts (19). 
To confi  rm immune-mediated antitumor activity in the 
sildenafi  l-treated groups, we performed an in vivo cytotoxic-
ity assay. BALB/c mice were injected with PBS (naive), vac-
cinated with γ-irradiated CT26WT or C26GM, or challenged 
with CT26WT or C26GM tumors on day 0. On day 12 
(CT26WT) or day 5 (C26GM), all mice received carboxy-
fl  uorescein diacetate succinimidyl ester (CFSE)–labeled sple-
nocytes pulsed with the MHC class I–restricted AH-1 peptide 
(CFSEhigh), admixed with CFSE-labeled splenocytes pulsed 
with the irrelevant hemagglutinin (HA)-peptide (CFSElow). 
In vivo T cell cytotoxicity was determined 40 h later (Fig. 2). 
Figure 1.  PDE5 inhibition imparts a measurable immune-mediated 
antitumor effect. BALB/c or BALB/c Rag-2−/− mice were challenged s.c. 
with 0.5 × 106 CT26WT (A), C26GM colon carcinoma (B), or TS/A mam-
mary adenocarcinoma (C) cells. (D) C57BL/6 mice were challenged with 
0.5 × 106 MCA203 s.c. PDE5 inhibitors were started on day 0. Sildenafi  l 
was added to the drinking water or given i.p. daily. Tadalafi  l was given i.p. 
daily where indicated in B. Error bar values are shown.JEM VOL. 203, November 27, 2006  2693
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These time points were chosen based on the kinetics of 
tumor outgrowth observed in Fig. 1 A and Fig. 1 B, re-
spectively, when tumor size signifi  cantly diff  ered between 
untreated and sildenafi  l-treated mice. As expected, an endog-
enous AH1-specifi  c immune response was observed in the 
vaccinated mice as compared with their tumor-bearing counter-
parts. PDE5 inhibition in the vaccine-primed mice failed 
to augment antigen-specifi  c CD8 responsiveness compared 
with no treatment. In contrast, tumor-bearing mice treated 
with sildenafi  l early after tumor challenge generated antigen-
specifi   c immunity that was signifi   cantly greater then that 
observed in their untreated counterparts and similar, or even 
superior, to that induced by vaccination. Collectively, this is 
the fi  rst indication that PDE5 inhibitors can modulate anti-
tumor immunity. Because the sildenafi  l-mediated antitumor 
immune response does not completely eradicate tumors, tu-
mor escape mechanisms may be associated with their out-
growth. To test this hypothesis, the parental CT26WT cell 
line, as well as the CT26 tumor removed on day 24 from 
sildenafi  l-treated mice (either AH-1 pulsed or unpulsed), and 
BALB/c splenocytes were incubated with either AH-1 peptide-
primed (Fig. S1 C) or tumor-primed (Fig. S1 D) eff  ector 
T cells. Although eff  ector T cells recognized the parental 
CT26WT line and released IFN-γ in the assay, they failed to 
recognize the sildenafi  l-derived tumor. Its recognition, how-
ever, was restored by loading the sildenafi  l-derived tumor 
with the AH-1 peptide. (Fig. S1, C and D). These results 
suggest that the immune response in sildenafi  l-treated mice 
does not result in complete tumor eradication but rather in 
the selection of antigen-escape variants.
PDE5 inhibition synergizes with adoptive cell therapy (ACT) 
to delay tumor outgrowth
Considering that sildenafi   l treatment signifi  cantly  delayed 
tumor outgrowth but failed to eradicate it, we sought to de-
termine whether combining sildenafi  l with tumor-specifi  c 
CD8+ lymphocytes could enhance the therapeutic effi   cacy of 
ACT. 1 d after tumor challenge, C26GM-bearing mice re-
ceived purifi  ed CD8+ T cells derived from mice vaccinated 
with γ-irradiated C26GM cells. After adoptive transfer of 
these vaccine-primed CD8+ T cells, the mice were either 
Figure 2.  Sildenafi  l enhances antitumor CTL activity in vivo. 
(A) BALB/c mice were either challenged with CT26WT cells, vaccinated 
with 106 γ-irradiated CT26WT cells, or injected with PBS on day 0. 
Sildenafi  l was added to the drinking water where indicated. On day 12, 
all groups received 107 AH-1–pulsed CFSEhigh-labeled BALB/c splenocytes 
admixed with 107 HA-pulsed CFSElow-labeled BALB/c splenocytes. The mice 
were killed 40 h later. Single cell suspensions from spleens and tumor 
draining lymph nodes were analyzed by FACS. (B) BALB/c mice were either 
challenged with C26GM cells, vaccinated with 106 γ-irradiated C26GM 
cells, or injected with PBS on day 0. Sildenafi  l was added to the drinking 
water on day 0. After 5 d, the mice received CFSE-labeled target spleno-
cytes as described in A. Analysis was performed as described in the 
Materials and methods.
Figure 3.  Sildenafi  l improves the effi  cacy of ACT. BALB/c mice were 
challenged s.c. with either C26GM (A) or 4T1-HA (B) cells on day 0. 
Tumor-specifi  c T cells were transferred on day 1. Sildenafi  l treatment was 
started on day 1. Tumors were surgically removed and weighed (right) 
either on day 10 (A) or 21 (B). *, PA < 0.00001 by using one-way ANOVA; 
+, PT < 0.001 by using a paired t test comparing sildenafi  l to sildenafi  l + 
ACT groups. Error bar values are shown.2694  VIAGRA INCREASES ANTITUMOR IMMUNITY | Serafi  ni et al.
treated with sildenafi  l or left untreated. Although adoptive 
transfer alone demonstrates no statistically meaningful anti-
tumor eff  ect compared with no treatment (Fig. 3 A), PDE5 
  inhibition signifi  cantly reduces tumor outgrowth. However, 
coupling adoptive immunotherapy with PDE5 inhibition 
  resulted in the greatest antitumor eff  ect.
To extend this fi  nding to other models, the experiment 
was repeated using the 4T1 mammary carcinoma genetically 
modifi  ed to express the infl  uenza-derived HA as a model tu-
mor antigen (Fig. 3 B). Mice were challenged on day 0 with 
0.5 × 106 4T1-HA cells. On the next day they received 3 × 
106 HA-specifi  c naive CD8+ T cells. After adoptive transfer, 
the mice were either treated with sildenafi  l or left untreated. 
As with the C26GM experiments, no therapeutic benefi  t was 
observed with ACT alone, whereas sildenafi  l + ACT imparted 
the greatest antitumor benefi  t. Sildenafi  l treatment alone, 
  instead, substantially delayed tumor progression in immuno-
competent BALB/c mice but not in immune-defi  cient 
Rag-2−/− mice (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20061104/DC1). These data confi  rm  the 
immunomodulatory properties of PDE5 inhibitors in aug-
menting the therapeutic effi   cacy of ACT and demonstrate a 
role of sildenafi  l in modifying the tumor microenvironment 
rendering it more susceptible to CTL-mediated cytotoxicity.
PDE5 inhibition increases tumor-infi  ltrating CD8+ T cells
To exert a measurable antitumor eff  ect, tumor-specifi  c T cells 
must be present in suffi   cient numbers and capable of traffi   ck-
ing to their targets. A direct correlation exists between the 
number of tumor-infi  ltrating lymphocytes (TILs) and a favor-
able clinical outcome, as demonstrated in patients with meta-
static ovarian cancer (20). Furthermore, the functional status of 
TILs has been correlated with a favorable prognosis in vari-
ous human malignancies (20–24). Because PDE5 inhibition 
augments antitumor immunity, we asked whether sildenafi  l 
treatment altered both the number and activation state of 
TILs. Histological examination of CT26WT tumors revealed 
a greater intratumoral cellular infi  ltrate in the sildenafi  l-treated 
mice compared with the untreated controls (Fig. 4 A). To bet-
ter evaluate these diff  erences, C26GM-bearing mice received 
either tumor-primed or no T cells followed by sildenafi  l treat-
ment or no additional therapy. The tumors were excised 9 d 
later, and single cell suspensions were obtained. The T cell in-
fi  ltrate was analyzed by fl  ow cytometry for CD4+ and CD8+ 
T cells. This approach enabled us to accurately examine the 
entire tumor mass and reliably quantify the infi  ltrating lym-
phocytic population. Although no increase in CD4+ T cells 
was observed with PDE5 inhibition (Fig. 4 B, inset), sildenafi  l 
treatment greatly increased CD8+ intratumoral infi  ltration 
with up-regulation of the activation markers CD69 and CD25 
(Fig. 4 C). There were no diff  erences in activation markers 
between the sildenafi  l-treated group and sildenafi  l + ACT, 
whereas a signifi  cant increase in intratumoral T cells were 
  observed in the sildenafi  l + ACT–treated group compared 
with sildenafil alone (Fig. 4 B and Fig. S4, available 
at http://www.jem.org/cgi/content/full/jem.20061104/DC1).
To determine whether the immunomodulatory eff  ect of 
PDE5 inhibition aff  ected T cell activation within the tumor 
microenvironment, we examined IL-2 production by TILs 
using a transgenic mouse in which expression of GFP is un-
der an IL-2 promoter (BALB/c–IL-2p/GFP) (25). In this 
model, T cell stimulation activates the IL-2 promoter and 
  results in expression of the reporter transgene, GFP, which is 
easily detectable by fl  ow cytometry. C26GM-primed BALB/
c–IL-2p/GFP splenocytes were adoptively transferred into 
tumor-bearing recipients that were either left untreated or 
treated with sildenafi  l for 9 d. Single cell suspensions of the 
tumor-infi  ltrating CD8+ T cells were analyzed by fl  ow cy-
tometry for GFP expression. Adoptively transferred, vaccine-
primed T cells were activated in the tumor microenvironment 
only in the presence of PDE5 inhibition, whereas in its ab-
sence they produced no IL-2 and, hence, were bona fi  de an-
ergic T cells (Fig. 4 D). To further prove that these eff  ects were 
dependent on CD8+ T cells, mice were challenged with 
C26GM and were (a) left untreated, (b) given sildenafi  l, (c) 
given an anti-CD8+ depleting antibody, or (d) given both 
sildenafi  l and the CD8+ depleting antibody. Sildenafi  l treat-
ment again demonstrated a statistically signifi  cant reduction 
in tumor outgrowth, an eff  ect completely abrogated by CD8+ 
depletion (Fig. 4 E). These experiments demonstrate that 
PDE5 inhibition enhances the tumor-specifi  c T cell response, 
increases intratumoral T cell infi  ltration and activation, and 
underscores the role of CD8+ T cells in sildenafi  l-mediated 
antitumor responses.
In vitro sildenafi  l down-regulates the myeloid suppressor 
cell suppressive marker IL-4R𝗂
The experiments described thus far demonstrate the ability of 
PDE5 inhibition to prime/augment antitumor immunity. Yet 
the mechanisms resulting in T cell activation are unknown. 
Because PDE5 is expressed in various cells of the immune 
system (including DCs, macrophages, and T cells [26]), PDE5 
inhibitors could putatively target these various populations. 
Furthermore, numerous factors are present in tumor-bearing 
hosts that could impair the generation of an eff  ective immune 
response such as the defective maturation of DCs (7), the ac-
cumulation of suppressive MDSCs (4), T cell anergy (27), 
and/or the accumulation of T reg cells (28). These popula-
tions were, therefore, examined separately. Flow cytometric 
analysis of sildenafi  l-treated or untreated mice failed to reveal 
important diff  erences in DC maturation, CD4+Foxp3+ T reg 
cells, or CD11b+/Gr-1+ MDSC accumulation (unpublished). 
We evaluated the eff  ect of in vitro PDE5 inhibition on puri-
fi  ed CD11c+, CD11b+, CD4+, and CD8+ cells isolated from 
C26GM tumor-bearing mice. This enabled us to examine 
purifi  ed populations, thereby eliminating the potential for ex-
ogenous infl  uences. Although sildenafi  l treatment increased 
the intracellular concentration of cGMP in all the popula-
tions examined (Fig. 5 A), it had no eff  ect on the proliferation 
of purifi  ed CD4+ and CD8+ T cells stimulated with either 
ConA (Fig. 5 B) or anti-CD3/CD28 beads (Fig. S5, available 
at http://www.jem.org/cgi/content/full/jem.20061104/DC1), JEM VOL. 203, November 27, 2006  2695
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nor on CD11c maturation (Fig. 5 C) as determined by B7.2 
or MHC class II up-regulation. It did, however, demonstrate 
the ability to reverse the suppressive phenotype of MDSCs. In 
light of recent data identifying IL-4Rα as a functional sup-
pressive marker for MDSCs (29), we examined IL-4Rα ex-
pression on CD11b+ cells cultured in the presence or absence 
of sildenafi  l. Fig. 5 D shows that sildenafi  l signifi  cantly de-
creases IL-4Rα expression on MDSCs, suggesting a down-
regulation of their suppressive pathways.
In vivo PDE5 inhibition down-regulates tumor-associated 
MDSC suppressive pathways
Although the hallmark feature of MDSCs is immunosuppres-
sion, emerging data reveal that the degree of immunosuppression 
Figure 4.  PDE5 inhibition increases intratumoral T cell infi  ltration 
and activation of tumor-specifi  c CD8+ T cells. (A) BALB/c mice were 
challenged with CT26WT cells s.c. on day 0, and 20 mg/kg/d sildenafi  l was 
added to the drinking water where indicated. The mice were killed 15 d 
later, and the tumors were stained with hematoxylin-eosin. (B–D) BALB/c 
mice were challenged with C26GM on day 0. They were treated with 
sildenafi  l, received 20 × 106 C26GM vaccine-primed splenocytes from 
H2d pIL-2/GFP mice, or were given both treatments as indicated. (B) The 
tumors were surgically removed 9 d later, and the CD8+ T cell infi  ltrate 
was determined by fl  ow cytometry. The percentage of CD8+ T cells was 
plotted against the tumor size at the time of tumor harvest. The software-
provided tool (Sigma plot) was used to fi  t a three-parameter exponential 
decay curve (y = 36.13 + 92xe−5.93x). Pearson bivariate correlation, 
P = 0.0000002. Data are derived from three independent experiments, 
with each containing fi  ve mice per group. (C) Intratumoral single cell 
suspensions were labeled with anti-CD25 or -CD69 antibodies. Data are 
expressed as the percentage of positive cells gated on the CD8+ T cell 
population. (D) IL-2 production in the ACT groups is reported as the per-
centage of GFP+ CD8+ T cells. Data are derived from two independent 
experiments. The paired t test p-value is reported. (E) BALB/c mice were 
challenged with 0.5 × 106 C26GM cells on day 0. They were treated with 
sildenafi  l starting on day 0, the anti-CD8+ depleting antibody, or both. 
The one-way ANOVA p-values (PA) are indicated. Data are reported from 
one of two similar experiments. Error bar values are shown.2696  VIAGRA INCREASES ANTITUMOR IMMUNITY | Serafi  ni et al.
varies among populations of MDSCs isolated from diff  erent 
organs, with intratumoral MDSCs being the most immuno-
suppressive. Interestingly, these MDSCs express greater levels 
of NOS2 and ARG1 than their splenic counterparts (5). 
ARG1 expression is mainly regulated by the STAT-6–IL-
4Rα pathway (30). We recently correlated IL-4Rα expression 
on CD11b+/Gr-1+ with an immunosuppressive phenotype 
(29), and our in vitro data (Fig. 5) indicate that sildenafi  l 
down-regulates IL-4Rα on MDSCs. We then asked whether 
in vivo PDE5 inhibition reduced ARG1 and NOS2 and 
down-regulated IL-4Rα in tumor-associated MDSCs. 
BALB/c mice were challenged with CT26WT, and half 
were treated with sildenafi  l. Mice were killed 15 d later, and 
intratumoral MDSCs were obtained. Sildenafi  l  increased 
cGMP (Fig. 6 A), reduced IL-4Rα expression (Fig. 6 B), and 
down-regulated NOS2 and ARG1 expression and reduced 
their enzymatic activity in the intratumoral MDSCs (Fig. 6, 
C and D). Considering that ARG1 and NOS2 are key en-
zymes in MDSC suppressive pathways (8, 31), these fi  ndings 
support the hypothesis that PDE5 inhibition is a novel phar-
macologic approach to regulate MDSC-mediated immuno-
suppressive pathways.
Gr-1+ cells are known to facilitate tumor outgrowth. 
As such, it is conceivable that strategies seeking to elimi-
nate this population may have a measurable antitumor eff  ect. 
In certain tumor models, the Gr-1 depleting antibody in-
hibited tumor outgrowth even in the absence of T cells, 
although the antitumor eff   ect was more pronounced in 
immune competent mice (32, 33). In light of these results 
and to verify that MDSCs are the target of sildenafi  l-
  mediated antitumor activity, we examined the eff  ect of 
  antibody-mediated MDSC depletion in combination with 
PDE5 inhibition in vivo. BALB/c mice were challenged 
on day 0 with C26GM tumor and were (a) left untreated; 
Figure 5.  Sildenafi  l down-regulates IL-4R𝗂 expression on CD11b+ 
cells. CD4+, CD8+, CD11b+, or CD11c+ cells were magnetically purifi  ed 
from spleens of C26GM-bearing mice challenged 9 d earlier. CD4+ or 
CD8+ T cells were stimulated with ConA for 3 d, with or without 50 μg/ml 
sildenafi  l. (A) Purifi  ed cells were cultured separately for 2 d with or with-
out sildenafi  l, harvested, and used to determine cGMP levels, as described 
in Materials and methods. (B) T cell proliferation was determined by 
[3H]thymidine incorporation. (C) CD11c+ cells were analyzed for B7.2 and 
MHC class II expression. (D) CD11b+ cells were analyzed for IL-4Rα ex-
pression by fl  ow cytometry. The t test p-value is reported. Error bar values 
are shown. MFI, multiplicity of infection.
Figure 6.  In vivo PDE5 inhibition down-regulates tumor-associated 
MDSC suppressive pathways. BALB/c mice were challenged with 0.5 × 
106 C26GM cells and treated with sildenafi  l starting on day 0 or left 
untreated for 9 d. CD11b+ cells were obtained from the tumors and used 
to measure (A) intracellular cGMP and (B) IL-4Rα surface expression by 
fl  ow cytometry. (C) Western blot analysis was performed for NOS2, ARG1, 
and β-actin expression on purifi  ed tumor-associated CD11b+ cells. (D) NO 
production was determined as the concentration of NO3-NO2 in the su-
pernatant, and arginase activity was determined on cell lysates and nor-
malized for the number of cells. (E) BALB/c mice were challenged with 
C26GM, treated with sildenafi  l or the anti–Gr-1 depleting antibody, both 
treatments, or left untreated. Best fi  t of the data was obtained by four-
parameter sigmoid curves. ANOVA p-values (PA) are reported. Error bar 
values are shown. MFI, multiplicity of infection.JEM VOL. 203, November 27, 2006  2697
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(b) injected with 100 μg of anti–Gr-1 antibody i.p. on days 
0, 3, and 6; (c) treated with sildenafi  l; or (d) treated with a 
combination of the two treatments. As shown in Fig. 6 E, 
Gr-1 depletion delayed tumor outgrowth similarly to 
PDE5 inhibition, whereas no synergistic eff  ect was seen 
with the combination. Collectively, these data demonstrate 
the immunosuppressive nature of Gr-1+ cells and the abil-
ity of PDE5 inhibition to reduce their suppressive pheno-
type in vivo.
PDE5 inhibition abrogates MDSC suppressive activity
Freshly isolated MDSCs suppress the in vitro proliferation of 
activated lymphocytes. Interestingly, the suppressive mecha-
nisms appear to be strain specifi  c. In the Th1 cell prone strain 
C57BL/6, it is mediated by NOS2 through NO production 
(34), whereas, in the mixed Th1/Th2 cell BALB/c strain, 
  suppression requires peroxynitrite formation via ARG1 and 
NOS2 coexpression (8) or l-arginine depletion secondary to 
ARG1 overexpression (35). Reductions of both ARG1 and 
NOS2 expression via PDE5 inhibition should aff  ect both 
suppressive pathways, resulting in less MDSC-mediated im-
munosuppression and, therefore, enhanced antigen-specifi  c 
T cell proliferation. To test this hypothesis, tumor-derived 
CD11b+ MDSCs were isolated from C26GM-bearing 
BALB/c mice. MDSC suppressive activity was determined by 
admixing MDSCs with CFSE-labeled HA-specifi  c  CD8+ 
(clone 4) or CD4+ (6.5) T cells pulsed with their relevant 
peptide in the presence or absence of sildenafi  l (Fig. 7, A and B). 
Although the addition of tumor-derived MDSCs signifi  -
cantly impaired antigen-specifi  c T cell proliferation as dem-
onstrated by the low percentage of CFSElow clonotypic T 
cells, sildenafi  l almost completely restored both CD4+ and 
CD8+ responsiveness of these antigen-specifi  c T cells. The 
absence of sildenafi  l-mediated enhancement in T cell func-
tion in the groups lacking CD11b+ cells underscores the 
targeted role of sildenafi  l on the MDSC population. Be-
cause in a Th1 cell–prone environment MDSC suppression 
is only NOS2 dependent (34), we examined the role of 
PDE5 in MDSCs in a C57BL/6 background where 
NOS2−/− mice are also available. CD11b+ MDSCs were 
isolated from either C57BL/6-NOS2+/+ or B16GM-bearing 
C57BL/6-NOS2−/− B16GM melanoma-bearing mice. 
A suppression assay was performed by stimulating OVA-
specifi  c CD4+ T cells with the relevant peptide in the pres-
ence or absence of MDSCs obtained from either NOS2+/+ 
or NOS2−/− tumor-bearing mice (Fig. 7 C). Although the 
addition of C57BL/6-NOS2+/+ MDSCs induced consider-
able T cell suppression, no suppression was observed with 
MDSCs from NOS2−/− mice. Furthermore, although PDE5 
inhibition reversed MDSC suppression in NOS2+/+ mice, 
sildenafi   l failed to augment T cell responsiveness in the 
NOS2−/−-derived MDSC suppression assay. These results 
confi  rm the role of NOS2 in MDSC-mediated T cell sup-
pression (Fig. 7 C) and underscore the ability of PDE5 inhi-
bition to reverse the two major suppressive pathways in 
MDSCs (ARG1 and NOS2).
PDE5 inhibition restores T cell proliferation in MM 
and head and neck cancer patients
Having demonstrated that PDE5 inhibition can impair 
MDSC suppressive mechanisms in BALB/c and C57BL/6 
tumor-bearing mice, we next sought to determine whether 
similar results could be obtained in humans. Head and neck 
cancers are known to be highly immunosuppressive. Their 
high levels of GM-CSF production are likely the major me-
diator of immune suppression observed in these patients and 
are probably responsible for the intratumoral infi  ltration by 
MDSCs (36). In fact, peripheral blood lymphocytes (PBLs) 
from these patients are functionally impaired in their ability 
Figure 7.  PDE5 inhibition reverts MDSC suppressive pathways. 
Splenic CD11b+ cells from C26GM tumor-bearing mice were isolated and 
added to CFSE-labeled splenocytes containing either (A) naive HA-specifi  c 
CD8+ (CL4) cells or (B) naive HA-specifi  c CD4+ (6.5) cells. The cultures 
were stimulated for 4 d with the relevant peptide in the presence or ab-
sence of 50 μg/ml sildenafi  l. Proliferation was evaluated as CFSE dilution 
by FACS analysis. (C) Splenic CD11b+ cells were magnetically purifi  ed from 
B16GM tumor-bearing C57BL/6-NOS+/+ or C57BL/6-NOS−/− mice and 
added to CFSE-labeled splenocytes containing naive OVA-specifi  c CD4+ T 
cells. The cultures were stimulated for 4 d with the relevant peptide in the 
presence or absence of 50 μg/ml sildenafi  l. Proliferation was evaluated as 
CFSE dilution by fl  ow cytometry. Data derived from one of two indepen-
dent experiments with similar results are reported. Error bar values are shown.2698  VIAGRA INCREASES ANTITUMOR IMMUNITY | Serafi  ni et al.
to be activated and to proliferate upon stimulation (37). Simi-
lar results were also seen in prostate cancer (38) and in non-
small cell cancer (35). Although this anergic state in solid 
tumors may be attributable to the ARG1- and/or NOS-
  dependent suppressive activity of MDSCs, MDSC-mediated 
immunosuppression has not been previously reported in hema-
tological malignancies. PBMCs from MM patients were stim-
ulated with anti-CD3/CD28 antibody-coated beads in the 
presence of N-(omega)-hydroxy-nor-l-arginine (NorNOHA; 
an ARG1-specifi  c  inhibitor),  NG-monomethyl-l-arginine 
(l-NMMA; an NOS2 inhibitor), both inhibitors, or neither. 
As shown in Fig. 8 A (top), T cell expansion was considerably 
enhanced in the presence of both NorNOHA and l-NMMA, 
whereas the single inhibitors failed to increase T cell prolifer-
ation over the baseline. Interestingly, sildenafi  l yielded results 
equivalent to the combination of NorNOHA and l-NMMA. 
These results suggest involvement of both ARG1 and NOS2 
in MDSC-mediated immunosuppression in myeloma and 
confi   rm the in vitro results demonstrating the ability of 
PDE5 inhibitors to aff  ect both pathways. Recent data from 
our lab identifi  ed human MDSCs as ARG+, CD14+ cells 
(unpublished data). We therefore examined T cell expan-
sion in CD14+-depleted PBMCs under the same conditions 
(Fig. 8 A, bottom). Although CD14+ depletion alone in-
creased CD3+ T cell expansion fourfold, pharmacologic 
  inhibitors failed to further enhance proliferation, suggesting 
that CD14+ cells are the mediators of ARG1- and NOS2-
mediated immunosuppression in MM. As seen with purifi  ed 
mouse T cells (Fig. 5 B), sildenafi  l also failed to enhance the 
CD3+ T cell proliferation of CD14-depleted PBMCs from 
cancer patients.
We next sought to determine whether we could re-
store T cell proliferation of PBMCs isolated from head and 
neck and MM patients stimulated with anti-CD3/CD28 
antibody-coated beads in the presence or absence of silde-
nafi  l. The expansion of CD4+ and CD8+ T cells obtained 
from MM or head and neck patients was signifi  cantly less 
than that observed using healthy donors (Fig. 8 B). In con-
trast, in the presence of sildenafi  l, PBMCs from MM and 
head and neck patients expanded similarly to sildenafi  l-
treated PBMCs from healthy donors (Fig.8 B). Interest-
ingly, qualitative diff  erences in T cell expansion emerged 
between the two malignancies. In head and neck patients, 
CD8+ T cell proliferation is restored with PDE5 inhibi-
tion while CD4+ lymphocyte expansion in the same con-
dition is only partially augmented. In contrast, CD4+ T 
cell proliferation is restored and minimal eff  ects are seen 
on CD8+ lymphocyte expansion with PDE5 blockade in 
myeloma (Fig. 8 B).
In summary, these data confi  rm that PDE5 inhibition 
can augment immune responsiveness through its effect on 
an accessory CD14+ population. Moreover, they suggest 
that the same immunosuppressive mechanisms found in 
mice are conserved in human malignancies and that PDE5 
can be a useful therapeutic approach to enhance tumor-
specifi  c immunotherapy.
D  I  S  C  U  S  S  I  O  N 
This is the fi  rst demonstration that PDE5 blockade exerts 
an indirect, immune-mediated, antineoplastic eff  ect through 
inhibition of MDSC-mediated immunosuppressive mecha-
nisms. These fi  ndings could establish a new role for PDE5 
Figure 8.  PDE5 inhibition restores proliferation of head and neck 
and myeloma lymphocytes. (A) Unfractionated or CD14-depleted PBMCs 
from MM patients were stimulated with anti-CD3/CD28 antibody–coated 
beads in the presence of NorNOHA, L-NMMA, both NorNOHA and L-NMMA, 
sildenafi  l, or no inhibitor. The CD3+ T cell expansion was measured 5 d 
later by fl  ow cytometry. (B) Ficoll-purifi  ed PBMCs from healthy donors 
(n = 4), head and neck cancer patients (H&N; n = 7), or MM patients 
(n = 7) were stimulated as described in A in the presence or absence of 
sildenafi  l. CD4+ and CD8+ T cell expansion was measured by fl  ow cytom-
etry 5 d later. Data are reported as fold change. t test p-values are reported. 
Horizontal lines represent the median, the 10th and 90th percentile.JEM VOL. 203, November 27, 2006  2699
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inhibition as a viable and eff  ective immunological adjunct in 
the treatment of various malignancies, thereby adding to the 
growing list of therapeutic applications of these agents. In 
this paper we show that PDE5 inhibition can signifi  cantly 
overcome the immunosuppressive mechanisms present in a 
tumor-bearing host to generate immune responses that are 
similar to (if not greater than) those observed in a non–
tumor-bearing, vaccine-primed host (Fig. 2). However, 
  although a CTL response can be elicited, PDE5 blockade is 
incapable of complete tumor eradication (Fig. S1). Several 
hypotheses may account for these fi   ndings. For example, 
chronic sildenafi  l blockade may up-regulate PDE5 expres-
sion, making it diffi   cult to achieve complete and long-term 
pharmacologic inhibition (39). Alternatively, the sildenafi  l-
mediated immune response against the self tumor-associated 
antigen can predominantly involve low affi   nity CD8+ T cells 
incapable of complete tumor cell killing. Finally, the tumor-
specifi  c immune response may ultimately result in immune 
editing of the tumor that escapes immune recognition (Fig. 
S1, C and D).
PDE5 blockade not only increases intratumoral CD8+ 
infi  ltration and activation but also enhances their tumoricidal 
activity (Fig. 2). The ability to favorably alter the intratu-
moral microenvironment, thereby permitting tumor-specifi  c 
T cells to directly interact with their targets, is critical for 
maximal antitumor immunity. Eff  ective immunotherapy re-
quires tumor-specifi  c CTLs to infi  ltrate the tumor and kill 
their target in situ. Although no clinical advantage was de-
rived by the presence of tumor-specifi  c CTLs in the periph-
eral blood in melanoma patients (40), their frequency in the 
tumor correlated with a favorable prognosis (41). These clini-
cal observations seem to be confi  rmed in our model where 
sildenafi  l treatment (a) increased the CD8+ T cell tumor in-
fi  ltration (Fig. 4 B) and (b) increased the percentage of acti-
vated T cells (Fig. 4, C and D). Moreover, the number of 
tumor-infi  ltrating T cells directly correlated with a measur-
able antitumor eff  ect (Fig. 3).
Although sildenafi  l can increase cGMP in T cells, DCs, 
and CD11b+ cells (Fig. 5), the following data indicate that 
Gr-1+/CD11b+ MDSCs are its primary cellular target. Gr-1 
depletion does not augment sildenafi  l-mediated antitumor 
activity (Fig. 6 E), and sildenafi  l down-regulates MDSC sup-
pressive pathways in vivo (Fig. 6, B–D). Moreover, sildenafi  l 
reverses MDSC suppression in vitro (Fig. 7). MDSCs and/or 
tumor-associated macrophages have been shown to induce 
apoptosis or anergy in CD8+ and CD4+ T cells through 
NOS2- and/or ARG1-dependent mechanisms (34). In fact, 
NO production anergizes Th1 cells through inhibition of 
IL-2 signaling (34). Alternatively, in a mixed Th1/Th2 cell 
environment where ARG-induced pathways also mediate 
immunosuppression, MDSCs produce NO and super-oxide 
radicals to generate peroxynitrites that induce apoptosis of 
activated CD8+ T cells (9). A greater understanding of the 
role of MDSCs in tumor-induced immune dysfunction (7, 
42) will establish the scientifi  c rationale for a targeted phar-
macologic approach to disrupt these suppressive mechanisms 
and may serve as an adjunct to immunotherapy. We previ-
ously showed that nitroaspirin could abrogate the inhibitory 
activity of MDSCs by enhancing the preventive and thera-
peutic effi   cacy of antitumor vaccines (43). However, despite 
its use as a vaccine adjuvant, nitroaspirin demonstrated no 
antitumor effi   cacy when used alone. In contrast, down-
  modulation of both ARG1 and NOS2 in MDSCs (Fig. 6) 
with PDE5 inhibitors eff  ectively abrogates MDSC-mediated 
immune suppression, resulting in a measurable antitumor re-
sponse (Fig. 1, Fig. 3, and Fig. 4). We have recently shown 
that to eff  ectively exert their suppressive function, MDSCs 
must (a) be activated by IFN-γ production from antigen-
stimulated T cells, (b) release their own IFN-γ, and (c) be 
responsive to IL-13 (29). Cooperation between these two 
cytokines leads to the activation of ARG1 and NOS2 en-
zymes. Sildenafi  l neither alters IFN-γ production from acti-
vated lymphocytes (not depicted) nor changes IL-13 and 
IFN-γ production from MDSCs (Fig. S6, available at 
http://www.jem.org/cgi/content/full/jem.20061104/DC1). 
Rather, PDE5 inhibition down-regulates IL-4Rα expression 
on MDSCs (Fig. 5 and Fig. 6), likely impairing their respon-
siveness to IL-13.
MDSCs can promote tumor growth not only by prevent-
ing tumoricidal CTL activity but also by supporting tumor 
angiogenesis. The Gr-1+/CD11b+ cells, in fact, produce 
high levels of the matrix metalloprotease 9, which regulates 
the bioavailability of vascular endothelial growth factor. The 
selective deletion of the matrix metalloprotease 9 gene in 
these cells abolishes their ability to promote tumor growth 
and inhibits tumor formation (44). Although PDE5 inhibi-
tion could also aff  ect these proangiogenic mechanisms, the 
lack of antitumor activity in sildenafi  l-treated Rag-2−/− mice 
(Fig. 1) and the dependence on CD8+ T cells (Fig. 4) would 
imply otherwise.
Although we have shown that PDE inhibitors reduce 
NOS2 and ARG1, the full mechanisms underlying these 
  eff  ects remain to be elucidated. One putative mechanism 
  involves the impact of these inhibitors on mRNA stability. 
cGMP destabilizes NOS2 mRNA by reducing the ubiqui-
tous mRNA binding protein, human antigen R (45). As 
such, destabilization of NOS2 mRNA via PDE5 inhibition 
would abrogate NO-mediated immunosuppression more 
  eff  ectively than would competitive inhibition of NO itself. 
However, because ARG1 mRNA does not possess adenylate/
uridylate-rich elements and has not been described to be 
  stabilized by human antigen R, other mechanisms are likely 
involved in PDE5-mediated down-regulation of ARG1. 
One possibility is that high levels of cGMP induced by PDE5 
blockade reduce the cytosolic Ca2+ concentration (46), lead-
ing to a reduction of the calcium-dependent protein kinase C 
activity (47) that in turn prevents up-regulation of IL-4Rα 
(48). The link between IL-4Rα and ARG1 in MDSCs is 
supported by recent data (29) demonstrating a direct correla-
tion between ARG1 expression and IL-4Rα expression. 
ACT of tumor-primed CD8 T cells completely eradicated a 
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mice in which IL-4Rα expression has been deleted in neu-
trophils and macrophages, whereas no eff  ect was seen in the 
control littermates (29). Our fi  ndings support these data by 
demonstrating that PDE5 blockade down-regulates IL-4Rα 
expression on tumor-infi  ltrating MDSCs (Fig. 6) and syner-
gizes with the adoptive transfer of tumor-primed CD8+ T 
cells (Fig. 3 and Fig. 4). This eff  ect appears to specifi  cally tar-
get MDSCs, because IL-4Rα expression on isolated CD11b+ 
cells from tumor-bearing mice is signifi  cantly reduced when 
co-cultured in the presence of sildenafi  l (Fig. 5). Collectively, 
these fi  ndings underscore the critical role of the IL-4Rα–
ARG1 pathway in MDSCs, as well as the use of PDE5 inhibitors 
as therapeutically eff  ective drugs to overcome tumor-induced 
immunosuppression.
Although most of the work to date on MDSCs has fo-
cused on mouse Gr-1+/CD11b+ cells, emerging data confi  rm 
the presence of these cells in human malignancies (7, 42, 49). 
In this paper we show that a nonlymphoid CD14+ popula-
tion mediates the hypo-responsiveness in PBLs from MM 
  patients. Although the low proliferative capacity may be 
caused by intrinsic T cell defects, an additional explanation 
for T cell unresponsiveness is the presence of a nonlymphoid 
suppressor population whose function is abrogated by PDE5 
inhibition. Evidence supporting this is the ability of sildenafi  l 
to augment the proliferative index of lymphocytes obtained 
from unfractionated PBMCs but not from purifi  ed CD4+ or 
CD8+ T cells (Fig. 8 and Fig. S6). The ability of sildenafi  l to 
restore proliferation of PBLs from both head and neck and 
myeloma patients suggests that the mechanisms found in mice 
also play a major role in cancer-mediated immunosuppression 
in two very diff  erent human malignancies.
Although drugs such l-NMMA, Nor-NOHA, NO-aspirin, 
or Vitamin D3 (4) have all been used in vitro and in mouse 
models to alter MDSC suppressive mechanisms, they have ei-
ther not been extensively tested in humans or have been found 
to be extremely toxic, as is the case with l-NMMA (50). In 
demonstrating the ability to use clinically available PDE5 in-
hibitors to overcome the MDSC-mediated immunosuppres-
sive pathways, these observations open the opportunity for the 
rapid translation of our preclinical fi  ndings into the clinic and 
give new hope for the development of more eff  ective immune-
based treatments for a broad range of human malignancies.
MATERIALS AND METHODS
Cell lines. The following cell lines were used: CT26, a carcinogen-  induced, 
undiff  erentiated colon carcinoma obtained from BALB/c mice (51); TS/A, 
a mouse mammary adenocarcinoma derived from BALB/c mice (52); 
MCA203, a C57BL/6-derived fi  brosarcoma (53); and B16-GM, a C57BL/6 
melanoma cell line genetically modifi  ed to secrete GM-CSF (54). The 
4T1-HA cell line was obtained by lentiviral transduction of 4T1 mammary 
carcinoma and was provided by K. Whartenby (Johns Hopkins University, 
Baltimore, MD). These cell lines were grown in DMEM or RPMI 1640 
(Invitrogen) with 10% FBS (Invitrogen). The C26GM cell line derived from 
the C26 colon carcinoma was genetically modifi  ed to produce GM-CSF (8) 
and was grown in the presence of 800 μg/ml G418.
Drugs and cytokines. Sildenafi  l (Pfi  zer) was dissolved in the drinking water 
(20 mg/kg/24 h), given i.p. daily where indicated (20 mg/kg/24 h), or added 
to the cell cultures (50 mg/ml). 2 mg/kg/24 h tadalafi  l (Lilly ICOS) was ad-
ministered i.p. In vivo treatments started on day 0 unless otherwise indicated.
NorNOHA and l-NMMA (Calbiochem) were used at 500 μM in vitro.
Mice and in vivo experiments. 4–6-wk-old BALB/c and C57BL/6 mice 
were purchased from Harlan. C57BL/6-NOS2−/− mice (strain B6;129P2-
Nos2tm1Lau) and control mice (strain B6;129PF2/J-100903) were purchased 
from the Jackson Laboratory. BALB/c-Rag-2−/− (17), clone 4 mice trans-
genic for the H-2Kd–restricted TCR recognizing the infl  uenza virus, HA 
peptide (HAp512–520) TCR-transgenic (6.5) mice recognizing the HAp110–120 
presented by I-Ed, and OT-II TCR-transgenic mice recognizing OVAp329–
337 presented by I-Ab were all bred in the Johns Hopkins University animal 
facility. BALB/c–pIL-2/GFP mice were a gift of C.T. Weaver (University 
of Alabama, Tuscaloosa, AL) (25). All mouse experiments were in accor-
dance with protocols approved by the Animal Care and Use Committee of 
the Johns Hopkins University School of Medicine. 0.5 × 106 tumor cells 
were injected s.c. in the inguinal area. Tumor measurements were performed 
with a caliper by measuring the largest diameter and its perpendicular length. 
The tumor size index is the average of the product of these diameters mea-
sured independently by two operators. Gr-1 depletion was performed by 
i.p. injection of 100 μg of anti–Gr-1 depleting antibody (clone RB6.8C5-18) 
per mouse on days 0, 3, and 6. CD8 depletion used 200 μg of the anti-CD8 
depleting antibody (clone 2.43) on days 0, 2, 4, and 6. All of the experiments 
were performed at least twice with fi  ve mice per group unless otherwise 
  indicated in the fi  gures.
In vivo CTL assay. BALB/c splenocytes were stained either with 5 μM 
CFSE (Invitrogen) for 10 min at 37°C and pulsed with the relevant AH-1 
MHC class I peptide (corresponding to amino acids 423–431 of gp70, 
SPSYVYHQF; CFSEhigh cells) or with 0.5 μM CFSE and pulsed with 
an irrelevant peptide (HA) as a control (CFSElow cells). 107 splenocytes 
(per population) were transferred i.v. to each host. The draining in-
guinal lymph nodes and spleens were harvested 40 h later and analyzed by 
FACS. Percent lysis was calculated as 1 − CFSEhigh/CFSElow normal-
ized by the same ratio in naive BALB/c mice (%lysis = 100 × {1 − 
[(CFSEhigh
exp/CFSElow
exp)/(CFSEhigh
BALB/c/CFSElow
BALB/c)]}).
Vaccination and ACT. The vaccine consisted of 106 γ-irradiated CT26 or 
C26GM cells injected s.c. For ACT experiments, mice were vaccinated on 
days  −14 and −7 before ACT in all four limbs with 106  γ-irradiated 
C26GM. The CD8+ T cells were negatively purifi  ed using the CD8+ isola-
tion kit (Miltenyi Biotec), and 3 × 106 CD8+ T cells were transferred per 
mouse. In the 4T1-HA experiments, HA-specifi  c CD8+ naive T cells were 
isolated from spleens and lymph nodes of pCL4-TCR mice.
Flow cytometry. Single cell suspensions from spleens or tumors were 
stained with PE-conjugated anti–mouse CD8 (CD8-PE; BD Biosciences), 
allophycocyanin-conjugated anti–mouse CD4 (CD4-allophycocyanin; BD 
Biosciences), FITC-conjugated anti–mouse CD11c, PE-conjugated anti–
mouse B7.2, cychrome (Cy)-conjugated anti–mouse MHC class II, or with 
allophycocyanin-conjugated anti–mouse CD11b (BD Biosciences) and PE-
conjugated anti–mouse Gr-1 (CD8-PE). IL-4Rα expression was determined 
on purifi  ed CD11b+ cells with PE-conjugated anti–mouse CD124 (BD 
Biosciences). Isotype-matched antibodies were used as controls, and live cells 
were gated based on 7-amino-actinomycin D, annexin V staining. Samples 
were run on a fl  ow cytometer (FACSCalibur; BD Biosciences), and the 
data were analyzed using FCSexpress software (v 2.0; De Novo Software).
Cell purifi  cation. CD11b+ purifi  cation was performed with mouse CD11b 
MicroBeads (Miltenyi Biotec). The positive and negative fractions were 
sorted with the LS columns according to the manufacturer’s instructions. 
CD11c+ cells were positively selected from splenocytes of tumor-bearing 
mice using mouse CD11c MicroBeads (Miltenyi Biotec). CD4+ or CD8+ T 
cells were negatively selected, using the CD4+ or CD8+ T cell isolation kit 
(Miltenyi Biotec), from CD11b-depleted splenocytes. CD14 depletion of JEM VOL. 203, November 27, 2006  2701
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human PBMCs was obtained by adding PE-labeled, anti–human CD14 
antibody (BD Biosciences). The CD14-negative population was collected 
using a cell sorter (FACSVantage SE; BD Biosciences).
Suppressive assay. 2 × 105 purifi  ed splenic or intratumoral CD11b+ cells 
were added to 106 clonotypic CFSE-labeled splenocytes. They were then 
peptide pulsed and cultured for 3 d in 96-well fl  at-bottom plates. Sildenafi  l 
was added where indicated in the fi  gures.
Proliferation assay. PBLs were obtained from MM or head and neck can-
cer patients after obtaining informed consent using an Institutional Review 
Board–approved protocol. Ficolled PBMCs were stimulated with anti-
CD3/28 antibody-coated Dynal beads (3:1 bead/T cell ratio) for 5 d in a 
96-well round-bottom plate and analyzed by fl  ow cytometry. Sildenafi  l was 
added where indicated in the fi  gures. Results are reported as fold change 
(number of activated cells/number of unactivated cells).
cGMP. cGMP was measured on purifi  ed CD11b+, CD11c+, CD4+, or 
CD8+ cells using the Cyclic GMP EIA kit (Cayman Chemical). Data anal-
ysis was performed with the workbooks available at http://www.
caymanchem.com/neptune/servlet/neptune/template/analysis%2CEIA.vm/a/z. 
Data are expressed as mean ± SE of quadruplicate wells.
Western blot. Lysates from purifi  ed cells were denaturated at 95°C for 
10 min and subjected to SDS-PAGE, and proteins were transferred overnight 
to polyvinylidene difl  uoride membranes. The membranes were incubated 
with a rabbit polyclonal anti-NOS2 antibody (Santa Cruz Biotechnology, 
Inc.), mouse anti-ARG1 antibody (a gift from Augusto C. Ochoa, Louisiana 
State University, New Orleans, LA), or a polyclonal rabbit anti-actin anti-
body (Sigma-Aldrich). Proteins were detected using the SuperSignal West 
Pico Chemiluminescent Substrate kit (Pierce Chemical Co.) according to 
the manufacturer’s instructions.
NO measurement. NO was measured using a nitrate/nitrite assay kit 
(Cayman Chemical) according to the manufacturer’s instructions. Results 
were normalized to 106 cells. Data are from triplicate wells.
Arginase assay. The arginase assay was performed as previously described 
(8) on purifi  ed intratumoral MDSCs.
Statistical analysis. Bivariate Pearson and analysis of variance (ANOVA) 
analyses were performed using SPSS (v 7.0). All experiments were 
  repeated at least twice, and all p-values were two sided (t test) or one 
sided (ANOVA).
Online supplemental material. Fig. S1 shows that PDE-5 inhibitors 
  reduce tumor growth but that persistent tumors show evidence of immune 
editing. In Fig. S2, the antitumor eff  ect of sildenafi  l is maintained even with 
delayed treatment. Fig. S3 shows that sildenafi  l increases CD8+ TILs. Fig. S4 
depicts sildenafi  l as it fails to induce an antitumor eff  ect in 4T1-HA–bearing 
Rag-2−/− mice. In Fig. S5, sildenafi  l fails to augment proliferation of puri-
fi  ed T cells. Fig. S6 shows that sildenafi  l does not alter IL-13 or IFN-γ pro-
duction from CD11b+ cells. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20061104/DC1.
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